A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...
Oncotarget published "High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC" which reported that the aim of this study was therefore to define ...
To coordinate their size and growth with current environmental conditions, cells rely on the mechanistic target of rapamycin complex 1 (mTORC1) pathway, which senses cellular stresses, growth factors, ...
Known as much for its complexity as its vital role in regulating cellular and organismal growth, the mechanistic target of rapamycin complex 1 (mTORC1) pathway has seemingly been acting in mysterious ...
A team of Whitehead Institute scientists has for the first time revealed the molecular structure of a critical growth regulator bound to its partner proteins, creating a fine-grained view of how they ...
Predictive gene signature for trabectedin efficacy in advanced soft‐tissue sarcoma: A Spanish group for research in sarcoma (GEIS) study. New soft tissue sarcoma (STS) transcriptomic clusters to ...
Novartis has offloaded two midphase mTORC1 inhibitors to PureTech Health. The agreement will see PureTech create a subsidiary, resTORbio, to move the assets into a phase 2b trial in diseases linked to ...
Am J Health Syst Pharm. 2010;67(24):2095-2106. The second mTOR complex, mTORC2, contains mTOR, mLST8, and several unique proteins, including rictor (rapamycin-insensitive companion of mTOR). Rapamycin ...
The mammalian target of rapamycin (mTOR) protein, a member of the phosphoinositide 3-kinase (PI3K)-related protein kinase (PIKK) family, has a central role in two growth-regulatory pathways that have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results